Amphastar Pharmaceuticals Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: Increased 5% to approximately $184 million from $174.4 million in Q2 2025.

Net Income: Slight decrease to $30.3 million; however, earnings per share rose to $0.67 from $0.64 year-over-year.

Adjusted Net Income: Remained flat at $40.8 million, with adjusted EPS increasing to $0.91 from $0.85.

Gross Margin: Improved to 51% from 50% in the previous year, driven by higher-margin product sales.

Cash Flow from Operations: Approximately $51.3 million.

Share Repurchase: $45 million worth of shares repurchased during the quarter.

2Strategic Updates and Business Highlights

Growth Pillars: Continued focus on expanding branded and differentiated commercial portfolio, advancing complex generic and biosimilar products, and progressing proprietary development programs.

Product Performance:

BAQSIMI: Net sales of $45.5 million, down 3% year-over-year, but total prescriptions increased by 17%.

Primatene MIST: Strong consumer demand despite a decline in reported net sales due to timing of shipments.

Ipratropium Bromide: Launched in April with strong early sales of $8.4 million.

Glucagon: Sales declined 42% to $11.9 million due to increased competition.

Regulatory Progress: Advancements in the development pipeline, including the initiation of a Phase I clinical program for AMP-101 (epinephrine nasal product).

3Forward Guidance and Outlook

Sales Growth: Maintained guidance for mid-single to high-single-digit sales growth for 2026, despite expected increased expenses related to IMS facility remediation.

Cost Expectations: Anticipated increase in expenses by $2 million to $3 million per quarter due to remediation efforts at IMS.

Capital Expenditures: Expected to increase at IMS but no change to the overall capital expenditure profile.

4Bad News, Challenges, or Points of Concern

FDA Warning Letter: IMS received a warning letter following an inspection, prompting remediation efforts that may require additional resources but are not expected to materially impact overall operations.

Competitive Pressures: Notable declines in glucagon sales due to increased competition; the product is not expected to return to growth.

Pricing Dynamics: BAQSIMI faced pricing pressures linked to 340B drug pricing program issues, with recovery efforts ongoing.

5Notable Q&A Insights

Operating Costs: Future R&D and SG&A expenses are expected to increase, particularly R&D as a percentage of sales.

IMS Facility: Revenue from IMS accounts for about a third of overall corporate sales; no immediate shutdowns anticipated, but quality checks are causing some delays.

Market Share Goals: Early success with the generic Atrovent launch, aiming for 50-80% market capture, though not fully achieved yet.

Insulin Aspart Program: On track for commercial launch in 2027, with ongoing clinical studies showing positive progress. Overall, Amphastar demonstrated solid financial performance and strategic execution in Q2 2026, while also facing challenges related to regulatory compliance and competitive pressures in certain product lines.